BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $23,913 | -9.0% | 333,748 | -10.6% | 0.10% | -8.0% |
Q1 2024 | $26,266 | -15.6% | 373,148 | -7.4% | 0.11% | -25.2% |
Q4 2023 | $31,107 | +1278.9% | 403,148 | +1116.2% | 0.15% | +1061.5% |
Q3 2023 | $2,256 | -92.8% | 33,148 | -91.4% | 0.01% | -92.3% |
Q2 2023 | $31,334 | +4.4% | 383,848 | -5.1% | 0.17% | -2.9% |
Q1 2023 | $30,013 | -0.7% | 404,548 | +11.0% | 0.17% | -8.9% |
Q4 2022 | $30,214 | -98.3% | 364,548 | +5840.2% | 0.19% | +1483.3% |
Q3 2022 | $1,743,000 | -18.1% | 6,137 | 0.0% | 0.01% | -14.3% |
Q2 2022 | $2,127,000 | -15.9% | 6,137 | +5.1% | 0.01% | 0.0% |
Q1 2022 | $2,528,000 | -25.3% | 5,837 | -10.7% | 0.01% | -17.6% |
Q4 2021 | $3,382,000 | +0.6% | 6,537 | -5.8% | 0.02% | -5.6% |
Q3 2021 | $3,361,000 | +7.6% | 6,937 | 0.0% | 0.02% | +12.5% |
Q2 2021 | $3,123,000 | +14.6% | 6,937 | -2.8% | 0.02% | +6.7% |
Q1 2021 | $2,726,000 | +20.3% | 7,137 | 0.0% | 0.02% | +7.1% |
Q4 2020 | $2,266,000 | +28.2% | 7,137 | 0.0% | 0.01% | +7.7% |
Q3 2020 | $1,768,000 | -64.5% | 7,137 | -62.2% | 0.01% | -38.1% |
Q2 2020 | $4,984,000 | – | 18,874 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |